Skip to main content

Table 2 Epidemiological studies of whole cannabis and cannabis extracts for anxiety (part 2)

From: Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties

Study Data Source Number Route of Administration Outcome
Cuttler et al. 2016 [59] Recruited via word-of-mouth and links on advertisements posted on various websites and in Washington State cannabis dispensaries 1418 participants Inhaled- (joints, bong, pipe, vaporiser) – (M) 89.8%, (F) 88%
Oral- (M) 3.9%, (F) 7.9%
Concentrates- (M) 5.4%, (F) 3.1%
Topical- (M & F) 0.4%
Other- (M) 0.6%, (F) 0.73%
Male: 55.3%
Female: 57.2%
Reported feeling less anxious or fearful
Corroon et al. 2017 [53] Recruited via social media 2774 participants N/A 46% reported using cannabis as a substitute for prescription drugs
Piper et al. 2017 [54] New England dispensary members 1513 participants N/A 71.8% reduced medication prescribed for anxiety
Corroon et al. 2018 [55] Recruited via social media. 2409 participants N/A Almost 62% of CBD users reported using CBD to treat a medical condition. The top three medical conditions were pain, anxiety, and depression
Feingold et al. 2018 [58] Data was drawn from Waves 1 and 2 of the National Epidemiologic survey on Alcohol and Related
3723 participants N/A Remission rates for non-users: 66.0%
Remission rates for users: 52.8%)
Cuttler et al. 2018 [57] Data from the cannabis tracking app StrainprintTM 5085 tracking sessions Inhalation (smoking, vaping, concentrates, dab bubbler, dab portable) 93.5% of sessions recorded decrease in anxiety